C-CHHWChronos Therapeutics
orexin-1 antagonist, dopamine transporter inhibitor, glioblastoma
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-CHHW
C-CHHWC-CHHWorexin-1 antagonist, dopamine transporter inhibitor, glioblastoma
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Chronos Therapeutics states that proprietary insights into the regulation of cellular chronological lifespan can be used to identify and advance therapeutics for age-related diseases quickly and efficiently, with a development strategy centered on both repurposing FDA/EMA-approved drugs and discovering novel proprietary lead candidates.
SourceChronos Therapeutics presents itself as a CNS specialist company focused on developing treatments for both degenerative and behavioural diseases of the brain and nervous system, while actively pursuing in-licensing and collaboration opportunities to expand or advance its portfolio.
SourceChronos Therapeutics states that proprietary insights into the regulation of cellular chronological lifespan can be translated quickly and efficiently into pre-clinical drug development for age-related diseases. Its stated strategic focus is both to reposition existing FDA/EMA-approved drugs and to discover novel proprietary lead candidates, especially for osteoporosis and neurodegenerative diseases.
SourceChronos Therapeutics stated that its proprietary understanding of the regulation of cellular chronological lifespan enables rapid and efficient advancement of research into pre-clinical development for age-related diseases. Its strategy combined repositioning FDA/EMA-approved drugs with discovery of novel proprietary lead candidates, focused on conditions such as osteoporosis and neurodegenerative diseases.
SourceChronos Therapeutics states that proprietary positions in the regulation of cellular chronological lifespan can be translated from discovery into pre-clinical development for treatments targeting age-related diseases. The company presents a focused development model built around two beliefs: that FDA-approved drugs can be repositioned for new therapeutic use, and that novel proprietary drug candidates can be discovered and advanced for diseases of ageing and neurodegeneration.
SourceNo Chronos Therapeutics belief, mission, or scientific position is visible in the provided 2018-03-31 Wayback capture text; the visible content is the Internet Archive/Archive Team wrapper, so no company-authored stance can be extracted from this snapshot alone.
Source